Skip to content

Few people with HIV starting raltegravir and dolutegravir change therapy because of side-effects

US regulator approves Gilead's Vosevi combo pill for hepatitis C retreatment

Many people living with HIV at high risk of cardiovascular disease are not on statins

People treated with atazanavir had lower risk of stroke and heart attack

Gay men using HIV self-tests promptly seek confirmatory testing and linkage to care, New York data suggests

Proton pump inhibitors may blunt CD4 cell gains, cause immune activation, in people with HIV

Non-alcoholic fatty liver disease common in people living with HIV – metabolic disorders are key risk factors

High uptake of home-based HIV testing in Zambia, but repeat visits needed to get close to universal coverage

Frailty is associated with loss of bone mineral density in middle-aged HIV-positive men and women